Published in Hepatitis Weekly, November 18th, 2002
Under the terms of the letter of agreement, CellExSys and Itochu plan to form a Japanese joint venture company that will be responsible for the development, sales, marketing, and manufacturing of CellExSys' potential cell therapy products in Japan.
David M. Schubert, CellExSys, said, "We believe that CellExSys' cell therapy technology has significant potential and we plan to begin clinical trials in hepatitis B as early as 2003 in the United States with additional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.